Przegląd Gastroenterologiczny

Abstract

2/2022 vol. 17
Letter to the Editor

Inflammatory bowel disease induced by bimekizumab

Dominika Wietrzykowska-Grishanovich 1
,
Maciej Pleskacz 1
,
Radosław Kempiński 2
  1. Department of Gastroenterology and Hepatology, University Hospital, Wroclaw, Poland
  2. Department of Gastroenterology and Hepatology, University Hospital, Wroclaw Medical University, Wroclaw, Poland
Gastroenterology Rev 2022; 17 (2): 175–176
DOI: https://doi.org/10.5114/pg.2022.116374
Online publish date: 2022/05/19
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
Inflammatory bowel disease (IBD) is a chronic condition of the gastrointestinal tract, with a complex aetiopathogenesis in which genetic, immunological, and environmental factors are being discussed. The development of knowledge about molecular processes and the aetiology of diseases are made possible the implementation of modern therapies with biological drugs, which are a heterogeneous group of substances working by modulating the body’s immune response. Currently, biological medications are used in an increasing number of indications.
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
integrated with publons
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications